SCHEMBL264038

SCHEMBL264038

Cc1nc(-c2ccc(C(F)(F)F)[n+]([O-])c2)sc1CCO[N+](=O)[O-]

nearest known ligand 0.38

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
LMNA P02545 1/20 0.38
PPARD Q03181 7/20 0.38
PPARA Q07869 6/20 0.38
PPARG P37231 5/20 0.38
TP53 P04637 4/20 0.38
PTPN1 P18031 3/20 0.36
FFAR1 O14842 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260007 0.83 PPARD (0.53) MAPTPPARDPPARAPPARGFFAR1
SCHEMBL14210415 0.82 PPARD (0.39) MAPTLMNAPPARDPPARAPPARG
SCHEMBL264030 0.80 PPARD (0.41) MAPTLMNAPPARDPPARAPPARG
SCHEMBL263525 0.79 PPARD (0.49) MAPTLMNAPPARDPPARAPPARG
SCHEMBL260575 0.79 TP53 (0.39) MAPTLMNAPPARDTP53FFAR1
SCHEMBL261446 0.79 MAPT (0.46) MAPTLMNAPPARDTP53FFAR1
SCHEMBL260283 0.78 PPARD (0.51) MAPTLMNAPPARDPPARAPPARG
SCHEMBL260340 0.77 MAPT (0.51) MAPTLMNAPPARDPPARAPPARG
SCHEMBL4816726 0.77 ALDH1A1 (0.52) MAPTLMNAPPARDPPARAPPARG
SCHEMBL260156 0.77 MAPT (0.39) MAPTLMNAPPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968575-B2 Nitric oxide donors and uses thereof RENOPHARM LTD. (IL) 2011-06-28 US claimed
US-8134010-B2 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease RENOPHARM LTD. (IL) 2012-03-13 US disclosed
US-7968575-B2 Nitric oxide donors and uses thereof RENOPHARM LTD. (IL) 2011-06-28 US disclosed
US-7579477-B2 Thiazole-based nitric oxide donors having alkyl substituent(s) and uses thereof RENOPHARM LTD. (IL) 2009-08-25 US disclosed
US-7498445-B2 Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof RENOPHARM LTD. (IL) 2009-03-03 US disclosed
US-7368577-B2 Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof RENOPHARM LTD. (IL) 2008-05-06 US disclosed
US-7368577-B2 Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof RENOPHARM LTD. (IL) 2008-05-06 US disclosed
US-7332513-B2 Thiazole-based nitric oxide donors having acyl substituent(s) and uses thereof RENOPHARM LTD. (IL) 2008-02-19 US disclosed
US-7189750-B2 Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof RENOPHARM LTD. (IL) 2007-03-13 US disclosed
US-20070021382-A1 Nitric oxide donors and uses thereof RENOPHARM LTD. (IL) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021382-A1 Nitric oxide donors and uses thereof NOS2, NOS1, NOS3 MAPT 4219/4885LMNA 3973/4885PPARD 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.